Cargando…
Enzymatic Late‐Stage Modifications: Better Late Than Never
Enzyme catalysis is gaining increasing importance in synthetic chemistry. Nowadays, the growing number of biocatalysts accessible by means of bioinformatics and enzyme engineering opens up an immense variety of selective reactions. Biocatalysis especially provides excellent opportunities for late‐st...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359417/ https://www.ncbi.nlm.nih.gov/pubmed/33453143 http://dx.doi.org/10.1002/anie.202014931 |
_version_ | 1783737545548365824 |
---|---|
author | Romero, Elvira Jones, Bethan S. Hogg, Bethany N. Rué Casamajo, Arnau Hayes, Martin A. Flitsch, Sabine L. Turner, Nicholas J. Schnepel, Christian |
author_facet | Romero, Elvira Jones, Bethan S. Hogg, Bethany N. Rué Casamajo, Arnau Hayes, Martin A. Flitsch, Sabine L. Turner, Nicholas J. Schnepel, Christian |
author_sort | Romero, Elvira |
collection | PubMed |
description | Enzyme catalysis is gaining increasing importance in synthetic chemistry. Nowadays, the growing number of biocatalysts accessible by means of bioinformatics and enzyme engineering opens up an immense variety of selective reactions. Biocatalysis especially provides excellent opportunities for late‐stage modification often superior to conventional de novo synthesis. Enzymes have proven to be useful for direct introduction of functional groups into complex scaffolds, as well as for rapid diversification of compound libraries. Particularly important and highly topical are enzyme‐catalysed oxyfunctionalisations, halogenations, methylations, reductions, and amide bond formations due to the high prevalence of these motifs in pharmaceuticals. This Review gives an overview of the strengths and limitations of enzymatic late‐stage modifications using native and engineered enzymes in synthesis while focusing on important examples in drug development. |
format | Online Article Text |
id | pubmed-8359417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83594172021-08-17 Enzymatic Late‐Stage Modifications: Better Late Than Never Romero, Elvira Jones, Bethan S. Hogg, Bethany N. Rué Casamajo, Arnau Hayes, Martin A. Flitsch, Sabine L. Turner, Nicholas J. Schnepel, Christian Angew Chem Int Ed Engl Reviews Enzyme catalysis is gaining increasing importance in synthetic chemistry. Nowadays, the growing number of biocatalysts accessible by means of bioinformatics and enzyme engineering opens up an immense variety of selective reactions. Biocatalysis especially provides excellent opportunities for late‐stage modification often superior to conventional de novo synthesis. Enzymes have proven to be useful for direct introduction of functional groups into complex scaffolds, as well as for rapid diversification of compound libraries. Particularly important and highly topical are enzyme‐catalysed oxyfunctionalisations, halogenations, methylations, reductions, and amide bond formations due to the high prevalence of these motifs in pharmaceuticals. This Review gives an overview of the strengths and limitations of enzymatic late‐stage modifications using native and engineered enzymes in synthesis while focusing on important examples in drug development. John Wiley and Sons Inc. 2021-03-08 2021-07-26 /pmc/articles/PMC8359417/ /pubmed/33453143 http://dx.doi.org/10.1002/anie.202014931 Text en © 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Romero, Elvira Jones, Bethan S. Hogg, Bethany N. Rué Casamajo, Arnau Hayes, Martin A. Flitsch, Sabine L. Turner, Nicholas J. Schnepel, Christian Enzymatic Late‐Stage Modifications: Better Late Than Never |
title | Enzymatic Late‐Stage Modifications: Better Late Than Never |
title_full | Enzymatic Late‐Stage Modifications: Better Late Than Never |
title_fullStr | Enzymatic Late‐Stage Modifications: Better Late Than Never |
title_full_unstemmed | Enzymatic Late‐Stage Modifications: Better Late Than Never |
title_short | Enzymatic Late‐Stage Modifications: Better Late Than Never |
title_sort | enzymatic late‐stage modifications: better late than never |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359417/ https://www.ncbi.nlm.nih.gov/pubmed/33453143 http://dx.doi.org/10.1002/anie.202014931 |
work_keys_str_mv | AT romeroelvira enzymaticlatestagemodificationsbetterlatethannever AT jonesbethans enzymaticlatestagemodificationsbetterlatethannever AT hoggbethanyn enzymaticlatestagemodificationsbetterlatethannever AT ruecasamajoarnau enzymaticlatestagemodificationsbetterlatethannever AT hayesmartina enzymaticlatestagemodificationsbetterlatethannever AT flitschsabinel enzymaticlatestagemodificationsbetterlatethannever AT turnernicholasj enzymaticlatestagemodificationsbetterlatethannever AT schnepelchristian enzymaticlatestagemodificationsbetterlatethannever |